{"disease":{"id":"renal-cell-cancer","name":"renal cell cancer"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT00001238","title":"Von Hippel-Lindau (VHL): Clinical Manifestations, Diagnosis, Management and Molecular Bases of Inherited Renal and Other Urologic Malignant Disorders","phase":"","overall_status":"RECRUITING","enrollment_count":5000,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT07117227","title":"Validation of RCC Predicting Model With Emulated-target Trial","phase":"","overall_status":"RECRUITING","enrollment_count":4700,"lead_sponsor_name":"Peking University Third Hospital","has_results":false},{"nct_id":"NCT06714916","title":"Optimising Renal Tumour Management Through Artificial Intelligence Modules","phase":"","overall_status":"RECRUITING","enrollment_count":2100,"lead_sponsor_name":"Shao Pengfei","has_results":false},{"nct_id":"NCT00326898","title":"Sunitinib Malate or Sorafenib Tosylate in Treating Patients With Kidney Cancer That Was Removed By Surgery","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1943,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT01235962","title":"A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":1538,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT05176483","title":"Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors","phase":"PHASE1","overall_status":"RECRUITING","enrollment_count":1314,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT03793166","title":"Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":1175,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT05363072","title":"A Study to Describe the Kidney Cancer Patient Population Treatment, and Results in the Hospital District of Southwest Finland.","phase":"","overall_status":"COMPLETED","enrollment_count":1112,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT05056077","title":"Improving Nutrition and Physical Activity for Cancer Survivors (Tools To Be Fit)","phase":"NA","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"University of California, San Francisco","has_results":false},{"nct_id":"NCT07004426","title":"Symptomatic and Incidental RCC Detection","phase":"","overall_status":"COMPLETED","enrollment_count":1000,"lead_sponsor_name":"Charles University, Czech Republic","has_results":false},{"nct_id":"NCT03896958","title":"The PIONEER Initiative: Precision Insights On N-of-1 Ex Vivo Effectiveness Research Based on Individual Tumor Ownership (Precision Oncology)","phase":"","overall_status":"UNKNOWN","enrollment_count":1000,"lead_sponsor_name":"SpeciCare","has_results":false},{"nct_id":"NCT05621837","title":"Quantifying Systemic Immunosuppression to Personalize Cancer Therapy","phase":"","overall_status":"RECRUITING","enrollment_count":1000,"lead_sponsor_name":"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano","has_results":false},{"nct_id":"NCT06829888","title":"Percutaneous Tumor Ablation Vs Partial Nephrectomy for Small Renal Mass: the Impact of Histologic Variant and Tumor Size","phase":"","overall_status":"COMPLETED","enrollment_count":955,"lead_sponsor_name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","has_results":false},{"nct_id":"NCT03170960","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":914,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT02684006","title":"A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)","phase":"PHASE3","overall_status":"COMPLETED","enrollment_count":886,"lead_sponsor_name":"Pfizer","has_results":true},{"nct_id":"NCT07223424","title":"Patient Preference for Subcutaneous vs. Intravenous Immune Therapy","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":880,"lead_sponsor_name":"Diwakar Davar","has_results":false},{"nct_id":"NCT03055013","title":"Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":819,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT06088134","title":"Contrast-enhanced CT-based Deep Learning Model for Preoperative Prediction of Disease-free Survival (DFS) in Localized Clear Cell Renal Cell Carcinoma (ccRCC)","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"Mingzhao Xiao","has_results":false},{"nct_id":"NCT05037825","title":"The Gut Microbiome and Immune Checkpoint Inhibitor Therapy in Solid Tumors","phase":"","overall_status":"RECRUITING","enrollment_count":800,"lead_sponsor_name":"VastBiome","has_results":false},{"nct_id":"NCT04140526","title":"Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC","phase":"PHASE1, PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":733,"lead_sponsor_name":"OncoC4, Inc.","has_results":false},{"nct_id":"NCT07383441","title":"Adding Biotherapy or Placebo to Standard Treatment for Advanced Kidney Cancer","phase":"PHASE3","overall_status":"NOT_YET_RECRUITING","enrollment_count":718,"lead_sponsor_name":"SWOG Cancer Research Network","has_results":false},{"nct_id":"NCT05078047","title":"Study Comparing the Standard Administration of IO Versus the Same IO Administered Each 3 Months in Patients in Response After 6 Months of Standard IO","phase":"PHASE3","overall_status":"RECRUITING","enrollment_count":646,"lead_sponsor_name":"UNICANCER","has_results":false},{"nct_id":"NCT07246759","title":"Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis","phase":"","overall_status":"NOT_YET_RECRUITING","enrollment_count":600,"lead_sponsor_name":"OncoHost Ltd.","has_results":false},{"nct_id":"NCT03455452","title":"Non-Interventional Study (NIS) of Nivolumab With or Without Ipilimumab in Participants With Advanced Kidney Cancer","phase":"","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":600,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":false},{"nct_id":"NCT04623502","title":"An Investigation of Kidney and Urothelial Tumor Metabolism in Patients Undergoing Surgical Resection and/or Biopsy","phase":"NA","overall_status":"RECRUITING","enrollment_count":600,"lead_sponsor_name":"University of Texas Southwestern Medical Center","has_results":false},{"nct_id":"NCT02983045","title":"A Dose Escalation and Cohort Expansion Study of NKTR-214 in Combination With Nivolumab and Other Anti-Cancer Therapies in Patients With Select Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":557,"lead_sponsor_name":"Nektar Therapeutics","has_results":true},{"nct_id":"NCT02568267","title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","phase":"PHASE2","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":534,"lead_sponsor_name":"Hoffmann-La Roche","has_results":false},{"nct_id":"NCT01631552","title":"Study of Sacituzumab Govitecan-hziy (IMMU-132) in Adults With Epithelial Cancer","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":515,"lead_sponsor_name":"Gilead Sciences","has_results":true},{"nct_id":"NCT04535921","title":"Fear of Cancer Recurrence in Genitourinary Cancer","phase":"","overall_status":"COMPLETED","enrollment_count":500,"lead_sponsor_name":"Ludwig-Maximilians - University of Munich","has_results":false},{"nct_id":"NCT05534854","title":"Frequency, Clinical Phenotype and Genetic Analysis of Heritable Kidney Cancer Syndromes","phase":"","overall_status":"UNKNOWN","enrollment_count":500,"lead_sponsor_name":"RenJi Hospital","has_results":false},{"nct_id":"NCT05863351","title":"Focused Radiation Versus Systemic Therapy for Kidney Cancer Patients With Limited Metastasis, SOAR Study","phase":"PHASE3","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":472,"lead_sponsor_name":"ECOG-ACRIN Cancer Research Group","has_results":false},{"nct_id":"NCT02178722","title":"Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers","phase":"PHASE1, PHASE2","overall_status":"COMPLETED","enrollment_count":444,"lead_sponsor_name":"Incyte Corporation","has_results":true},{"nct_id":"NCT05429866","title":"Immunological Variables Associated to ICI Toxicity in Cancer Patients","phase":"PHASE2","overall_status":"UNKNOWN","enrollment_count":441,"lead_sponsor_name":"Jules Bordet Institute","has_results":false},{"nct_id":"NCT03694912","title":"Development and Evaluation of High Risk Group Prediction Model in T1 Stage Renal Cell Cancer Using Molecular Biomarkers","phase":"","overall_status":"UNKNOWN","enrollment_count":426,"lead_sponsor_name":"Yonsei University","has_results":false},{"nct_id":"NCT03948724","title":"Impact of Therapeutic Patient Education on the Toxicity of Immune Checkpoint Inhibitors in Oncology","phase":"NA","overall_status":"COMPLETED","enrollment_count":411,"lead_sponsor_name":"Institut Cancerologie de l'Ouest","has_results":false},{"nct_id":"NCT03787056","title":"Predictive Value of Progastrin Titer at Diagnosis and of Progastrin Kinetics During Treatment in Cancer Patients","phase":"NA","overall_status":"RECRUITING","enrollment_count":410,"lead_sponsor_name":"Hospices Civils de Lyon","has_results":false},{"nct_id":"NCT06903312","title":"Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.","phase":"PHASE4","overall_status":"RECRUITING","enrollment_count":409,"lead_sponsor_name":"Fondazione Policlinico Universitario Agostino Gemelli IRCCS","has_results":false},{"nct_id":"NCT06885424","title":"A Long-Term Follow-Up Study of Participants Treated With A2 Biotherapeutics (A2 Bio) Gene Therapy (GT) Products","phase":"","overall_status":"ENROLLING_BY_INVITATION","enrollment_count":400,"lead_sponsor_name":"A2 Biotherapeutics Inc.","has_results":false},{"nct_id":"NCT06683846","title":"Ivonescimab in the Treatment of Multiple Advanced Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":400,"lead_sponsor_name":"Fudan University","has_results":false},{"nct_id":"NCT00730639","title":"A Phase 1 Study of Nivolumab (BMS-936558) in Subjects With Advanced or Recurrent Malignancies","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":395,"lead_sponsor_name":"Bristol-Myers Squibb","has_results":true},{"nct_id":"NCT00378703","title":"Bevacizumab, Sorafenib Tosylate, and Temsirolimus in Treating Patients With Metastatic Kidney Cancer","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":361,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":true},{"nct_id":"NCT03226886","title":"TRACERx Renal CAPTURE Sub-study","phase":"","overall_status":"UNKNOWN","enrollment_count":360,"lead_sponsor_name":"Royal Marsden NHS Foundation Trust","has_results":false},{"nct_id":"NCT02009449","title":"A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":353,"lead_sponsor_name":"Eli Lilly and Company","has_results":false},{"nct_id":"NCT03845166","title":"A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors","phase":"PHASE1","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":325,"lead_sponsor_name":"Exelixis","has_results":false},{"nct_id":"NCT04977453","title":"GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":317,"lead_sponsor_name":"GI Innovation, Inc.","has_results":false},{"nct_id":"NCT04787042","title":"Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067","phase":"PHASE1, PHASE2","overall_status":"RECRUITING","enrollment_count":316,"lead_sponsor_name":"Simcha IL-18, Inc.","has_results":false},{"nct_id":"NCT03207867","title":"A Phase 2 Study of NIR178 in Combination With PDR001 in Patients With Solid Tumors and Non-Hodgkin Lymphoma","phase":"PHASE2","overall_status":"TERMINATED","enrollment_count":315,"lead_sponsor_name":"Novartis Pharmaceuticals","has_results":true},{"nct_id":"NCT03866382","title":"Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":314,"lead_sponsor_name":"National Cancer Institute (NCI)","has_results":false},{"nct_id":"NCT02526017","title":"Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers","phase":"PHASE1","overall_status":"COMPLETED","enrollment_count":313,"lead_sponsor_name":"Five Prime Therapeutics, Inc.","has_results":true},{"nct_id":"NCT04258813","title":"Onco-primary Care Networking to Support TEAM-based Care","phase":"NA","overall_status":"ACTIVE_NOT_RECRUITING","enrollment_count":313,"lead_sponsor_name":"Duke University","has_results":false}],"total":50},"guidelines":[],"source":"Drug Landscape verified database"}